1.
|
Phase: Phase III, Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 001-0015-211, NCT00127387
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: MDA-ID-00156, NCI-3410, 3410, NCT00024167
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CALGB-90202, ECOG-CALGB-90202, NCT00079001, SWOG-CALGB-90202, CAN-NCIC-PRC2
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: SWOG-S0421, S0421, NCT00134056
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 30 and over
Sponsor: Other
Protocol IDs: 05-043, NCT00116142
|
|
6.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 553, NCT00132301
|
|
7.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: No age specified
Sponsor: Other
Protocol IDs: 05-8-4, NCT00243646
|
|
8.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E3805, E3805, NCT00309985
|
|
9.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-0521, NCT00288080
|
|
10.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: ROLL-GUP-0205-1, UCLA-0507059-01, NCT00336934
|
|
11.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-N0574, N0574, ACOSOG-N0574, NCT00377156
|
|
12.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: XRP6976J_3503, EudraCT#:2007-000323-17, NCT00514917
|
|
13.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EFC6546, EUDRACT : 2006-004756-20, NCT00519285
|
|
14.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D4320C00014, EUDRACT No 2007-003227-20, NCT00554229
|
|
15.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D4320C00033, NCT00617669
|
|
16.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: COU-AA-301, NCT00638690
|
|
17.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181120, NCT00676650
|
|
18.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA180-227, NCT00744497
|
|
19.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: COU-AA-302, NCT00887198
|
|
20.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: 424Sm32, NCT00121095
|
|
21.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181043, NCT00137436
|
|
22.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: UCSF-055513, NCI-7347, 7347, NCT00331344
|
|
23.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 90
Sponsor: Other
Protocol IDs: 0603, NCT00414388
|
|
24.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: IRB# 575-03, NCT00456989
|
|
25.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: UNC-LCCC-0420, LCCC 0420, NCT00225420
|
